RxDoctor Payments Data

Eugene Go, MD

Endocrinology, Diabetes & Metabolism · Port St John, FLNPI 1528052065

Payments from drug & device makers

$1,679in general payments, 2019–2025

Across 101 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$233
  • Novo Nordisk$210
  • Sunovion Pharmaceuticals Inc.$170
  • AstraZeneca$165
  • Merck$149
  • Mannkind Corporation$101
  • plus $650 from 13 others

What the payments were for

  • Food & beverage$1,66799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,679 in reported general payments places this provider in the 35th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$181,587
Medicare patients
628
Services billed
1,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide649$786,234
JardianceEmpagliflozin223$262,625
OzempicSemaglutide125$212,068
TrulicityDulaglutide180$208,018
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog85$79,549
Humulin R U-500 KwikpenInsulin Regular, Human28$73,023
FarxigaDapagliflozin Propanediol63$70,678
Tresiba Flextouch U-100Insulin Degludec81$66,354
Tresiba Flextouch U-200Insulin Degludec19$37,320
Humalog Kwikpen U-100Insulin Lispro94$33,466
Lantus SolostarInsulin Glargine,hum.Rec.Anlog189$32,597
Fiasp FlextouchInsulin Aspart (Niacinamide)27$28,252
SynthroidLevothyroxine Sodium309$26,187
JanumetSitagliptin Phos/Metformin Hcl26$23,910
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$23,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$92$1,000,487851 claims
Boehringer IngelheimJardiance, Tradjenta$75$278,426237 claims
Novo NordiskOzempic$210$212,068125 claims
AstraZenecaFarxiga$165$70,67863 claims
MerckJanumet, Januvia$149$45,95643 claims
AbbVieSynthroid$93$26,187309 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$233$24,27530 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$29$9,390688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Port St John

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →